{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T05:45:03Z","timestamp":1788414303364,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Casimersen is an antisense oligonucleotide used to treat patients with Duchenne muscular dystrophy (DMD), with mutations amenable to exon 45 skipping. However, real-world safety data are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study used the Food and Drug Administration Adverse Event Reporting System (FAERS) database to describe post-marketing adverse event reporting patterns associated with casimersen, identify disproportionality signals at the preferred term level, and characterize their onset patterns and affected organ systems.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>FAERS reports from 2004 to 2024 involving casimersen were extracted, deduplicated, and coded using the Medical Dictionary for Regulatory Activities (MedDRA). Disproportionality analyses were performed using four validated algorithms: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN) and Empirical Bayesian Geometric Mean (EBGM). Signals that met all four criteria were considered statistically significant. Time-to-onset and subgroup analyses according to age and sex were also performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 21,964,449 FAERS reports, 598 listed casimersen as the primary suspect, predominantly in males (98.5%) and patients aged\u2009&lt;\u200918\u00a0years (62.0%). The median time to AE onset was 253\u00a0days (range, 101\u2013490\u00a0days). Twenty-one System Organ Classes (SOCs) were implicated, including injury, poisoning, procedural complications (n\u2009=\u2009377), vascular disorders (n\u2009=\u200985), product issues (n\u2009=\u200980), and social circumstances (n\u2009=\u200913). Using all four algorithms, 30 significantly preferred terms (PTs) were identified, encompassing heterogeneous reporting categories, including clinically oriented terms as well as administration-related, medication use, and non-specific descriptors, such as product dose omission, poor venous access, proteinuria, hematuria, chromaturia, underdose, illness, and infusion-site extravasation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study characterized post-marketing adverse event reporting patterns associated with casimersen using FAERS data. By summarizing the preferred term\u2013level reporting distributions, affected organ system categories, and time-to-onset characteristics, the findings provide a descriptive overview of real-world reporting patterns following casimersen use. These results may inform post-marketing pharmacovigilance activities and support hypothesis generation in future studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11096-026-02103-5","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T07:09:11Z","timestamp":1772089751000},"page":"1048-1057","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of adverse event reporting with casimersen: a pharmacovigilance study based on the United States food and drug administration adverse event reporting system database"],"prefix":"10.1007","volume":"48","author":[{"given":"Zhenghua","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linmei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"issue":"1","key":"2103_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00248-3","volume":"7","author":"D Duan","year":"2021","unstructured":"Duan D, Goemans N, Takeda S, et al. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7(1):13. https:\/\/doi.org\/10.1038\/s41572-021-00248-3.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"2103_CR2","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41582-019-0203-3","volume":"15","author":"IEC Verhaart","year":"2019","unstructured":"Verhaart IEC, Aartsma-Rus A. Therapeutic developments for Duchenne muscular dystrophy. Nat Rev Neurol. 2019;15(7):373\u201386. https:\/\/doi.org\/10.1038\/s41582-019-0203-3.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"2103_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/01241398-200001000-00016","volume":"20","author":"CM Larson","year":"2000","unstructured":"Larson CM, Henderson RC. Bone mineral density and fractures in boys with Duchenne muscular dystrophy. J Pediatr Orthop. 2000;20(1):71\u20134.","journal-title":"J Pediatr Orthop"},{"issue":"3","key":"2103_CR4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s40618-021-01676-4","volume":"45","author":"A Catalano","year":"2022","unstructured":"Catalano A, Vita GL, Bellone F, et al. Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates. J Endocrinol Invest. 2022;45(3):517\u201325. https:\/\/doi.org\/10.1007\/s40618-021-01676-4.","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"2103_CR5","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1007\/s00415-023-11796-x","volume":"270","author":"M Chang","year":"2023","unstructured":"Chang M, Cai Y, Gao Z, et al. Duchenne muscular dystrophy: pathogenesis and promising therapies. J Neurol. 2023;270(8):3733\u201349. https:\/\/doi.org\/10.1007\/s00415-023-11796-x.","journal-title":"J Neurol"},{"issue":"10","key":"2103_CR6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","volume":"19","author":"TC Roberts","year":"2020","unstructured":"Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19(10):673\u201394. https:\/\/doi.org\/10.1038\/s41573-020-0075-7.","journal-title":"Nat Rev Drug Discov"},{"key":"2103_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1146\/annurev-med-041217-010829","volume":"70","author":"CF Bennett","year":"2019","unstructured":"Bennett CF. Therapeutic antisense oligonucleotides are coming of age. Annu Rev Med. 2019;70:307\u201321. https:\/\/doi.org\/10.1146\/annurev-med-041217-010829.","journal-title":"Annu Rev Med"},{"issue":"3","key":"2103_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/mus.27347","volume":"64","author":"KR Wagner","year":"2021","unstructured":"Wagner KR, Kuntz NL, Koenig E, et al. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: a randomized, double-blind, placebo-controlled, dose-titration trial. Muscle Nerve. 2021;64(3):285\u201392. https:\/\/doi.org\/10.1002\/mus.27347.","journal-title":"Muscle Nerve"},{"key":"2103_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cotox.2022.100373","author":"H Wu","year":"2022","unstructured":"Wu H, Wahane A, Alhamadani F, et al. Nephrotoxicity of marketed antisense oligonucleotide drugs. Curr Opin Toxicol. 2022. https:\/\/doi.org\/10.1016\/j.cotox.2022.100373.","journal-title":"Curr Opin Toxicol"},{"key":"2103_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.862508","volume":"13","author":"Y Shu","year":"2022","unstructured":"Shu Y, Ding Y, Liu Y, et al. Post-marketing safety concerns with secukinumab: a disproportionality analysis of the FDA adverse event reporting system. Front Pharmacol. 2022;13:862508. https:\/\/doi.org\/10.3389\/fphar.2022.862508.","journal-title":"Front Pharmacol"},{"key":"2103_CR11","unstructured":"Gliklich R, Dreyer N, Leavy M, eds. Registries for Evaluating Patient Outcomes: A User's Guide. Third edition. Two volumes. (Prepared by the Outcome DEcIDE Center [Outcome Sciences, Inc., a Quintiles company] under Contract No. 290 2005 00351 TO7.) AHRQ Publication No. 13(14)-EHC111. Rockville, MD: Agency for Healthcare Research and Quality. April 2014.\u00a0http:\/\/www.effectivehealthcare.ahrq.gov\/registries-guide-3.cfm.."},{"issue":"8","key":"2103_CR12","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2165\/00002018-200427080-00010","volume":"27","author":"EG Brown","year":"2004","unstructured":"Brown EG. Using MedDRA: implications for risk management. Drug Saf. 2004;27(8):591\u2013602. https:\/\/doi.org\/10.2165\/00002018-200427080-00010.","journal-title":"Drug Saf"},{"issue":"4","key":"2103_CR13","first-page":"1014","volume":"62","author":"A M\u00fcller","year":"2002","unstructured":"M\u00fcller A, Edmonston TB, Corao DA, et al. Exclusion of breast cancer as an integral tumor of hereditary nonpolyposis colorectal cancer. Cancer Res. 2002;62(4):1014\u20139.","journal-title":"Cancer Res"},{"issue":"6","key":"2103_CR14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u20136. https:\/\/doi.org\/10.1002\/pds.677.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"2103_CR15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","volume":"25","author":"A Szarfman","year":"2002","unstructured":"Szarfman A, Machado SG, O\u2019Neill RT. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database. Drug Saf. 2002;25(6):381\u201392. https:\/\/doi.org\/10.2165\/00002018-200225060-00001.","journal-title":"Drug Saf"},{"issue":"3","key":"2103_CR16","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1002\/cam4.5062","volume":"12","author":"Y Shu","year":"2023","unstructured":"Shu Y, Ding Y, He X et al.. Hematological toxicities in PARP inhibitors: a real-world study using FDA adverse event reporting system (FAERS) database. Cancer Med. 2023;12(3):3365\u201375. https:\/\/doi.org\/10.1002\/cam4.5062.","journal-title":"Cancer Med"},{"issue":"6","key":"2103_CR17","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1124\/dmd.121.000418","volume":"50","author":"F Alhamadani","year":"2022","unstructured":"Alhamadani F, Zhang K, Parikh R et al. Adverse drug reactions and toxicity of the Food and Drug Administration-approved antisense oligonucleotide drugs. Drug Metab Dispos. 2022;50(6):879\u201387. https:\/\/doi.org\/10.1124\/dmd.121.000418.","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"2103_CR18","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1046\/j.1432-1033.2003.03555.x","volume":"270","author":"J Kurreck","year":"2003","unstructured":"Kurreck J. Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem. 2003;270(8):1628\u201344. https:\/\/doi.org\/10.1046\/j.1432-1033.2003.03555.x.","journal-title":"Eur J Biochem"},{"issue":"7","key":"2103_CR19","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, et al.. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048.","journal-title":"Int J Med Sci"},{"issue":"4","key":"2103_CR20","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/pds.1323","volume":"16","author":"WP Stephenson","year":"2007","unstructured":"Stephenson WP, Hauben M. Data mining for signals in spontaneous reporting databases: proceed with caution. Pharmacoepidemiol Drug Saf. 2007;16(4):359\u201365. https:\/\/doi.org\/10.1002\/pds.1323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"2103_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s40264-015-0351-3","volume":"39","author":"MA Maci\u00e1-Mart\u00ednez","year":"2016","unstructured":"Maci\u00e1-Mart\u00ednez MA, de Abajo FJ, Roberts G et al. An empirical approach to explore the relationship between measures of disproportionate reporting and relative risks from analytical studies. Drug Saf. 2016;39(1):29\u201343. https:\/\/doi.org\/10.1007\/s40264-015-0351-3.","journal-title":"Drug Saf"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02103-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02103-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02103-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:16:08Z","timestamp":1778746568000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02103-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["2103"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02103-5","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"This study used publicly available anonymized data from the FAERS database and\ntherefore did not require institution al ethics approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}